That's the data that NN used to launch it. That's it's clinical indication. But off-label use is through the roof. More people use semaglutide for weight loss than T2DM. There is the demand. Much larger population. As they were saying in the clip, obesity is at record highs.
Semaglutide is the active ingredient.
Ozempic: T2DM
Wegovy: Weight loss.
Think about the cancer market population.
That's the data that NN used to launch it. That's it's clinical...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $519.7M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.4¢ | 7.0¢ | $1.222M | 16.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 942474 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 200000 | 2 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
0.000 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.3¢ | 7.0¢ | 6985767 | ||
| Last updated 15.59pm 14/05/2024 ? | |||||
| IMU (ASX) Chart |